What historical evidence establishes
The former Geref program documented a prescription-drug formulation, defined indications, and supervised protocols. The approval was later withdrawn after commercial discontinuation, not because of a finding that the drug was unsafe or ineffective.
Why that is not a research-vial schedule
- Product identity and formulation equivalence have not been established.
- The historical indication and study population may not match the current query.
- Hormone-axis evaluation and contraindications require clinical context.
What this evidence review covers
Present historical study protocols as historical evidence while rejecting modern research-product dose charts.
- Historical pediatric study protocol and population
- Older-adult study as separate context
- Why micrograms/kg and fixed-microgram charts cannot be generalized
- Regulated product versus vendor vial
- No calculator or blend conversion
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
historical trial context
The best-characterized protocol in the packet was studied in growth-hormone-deficient children under a historical multicenter protocol.
product/population boundary
Historical protocol details do not establish a dose for current adult wellness or research-vendor use.
| Evidence class | What the source supports |
|---|---|
| historical trial context | The best-characterized protocol in the packet was studied in growth-hormone-deficient children under a historical multicenter protocol. |
| product/population boundary | Historical protocol details do not establish a dose for current adult wellness or research-vendor use. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
GHRH(1-29) therapy in growth-hormone-deficient children
Evidence class: primary open label multicenter historical. What it supports: Historical n=110 pediatric regulated-product protocol, growth-velocity outcomes, and reported short-term safety measures.
What it does not establish: Adult anti-aging, weight loss, current research-vendor products, or a modern self-treatment dose.
FDA orphan designation and marketing-approval record for Geref
Evidence class: primary regulatory historical. What it supports: The historical regulated-product approval record and approved pediatric context.
What it does not establish: Current market availability or equivalence of products labeled sermorelin by research vendors.
Long-term GHRH(1-29) in age-advanced adults
Evidence class: primary historical human study. What it supports: Historical endocrine and metabolic observations in a defined older-adult study.
What it does not establish: Current anti-aging, bodybuilding, weight-loss, or research-product claims.
Questions this page answers
What was studied historically?
Show the exact pediatric population, protocol, duration, and source in a clearly labeled history table-not a recommendation card.
Can the historical dose be used for adults or blends?
No. Population, indication, formulation, and product identity differ.
What remains unresolved
- No validated current research-product schedule.
- No evidence for popular fixed-dose protocol language.
- No blend conversion evidence.